Creative BioMart to Present at BPS 2025 Annual Meeting | February 15-19, 2025

Active Recombinant Human TNFRSF18 protein, Fc/Avi-tagged, Biotinylated

Cat.No. : TNFRSF18-051H
Product Overview : Biotinylated Recombinant Human TNFRSF18(Gln26-Glu161) protein, fused to Fc/Avi tag at the C-terminus, was expressed in CHO cells .
  • Specification
  • Gene Information
  • Related Products
  • Download
Description : GITR (glucocorticoid-induced tumor necrosis factor receptor), also known as AITR and TNFRSF18, is a 40 kDa transmembrane glycoprotein that functions in immune regulation (1, 2). Mature human GITR consists of a 137 amino acid (aa) extracellular domain (ECD) with three tandem TNFR cysteine-rich repeats, a 21 aa transmembrane segment, and a 58 aa cytoplasmic domain (3, 4). Within the ECD, human GITR shares 55% and 60% aa sequence identity with mouse and rat GITR, respectively. Alternative splicing generates an isoform with a short deletion in the cytoplasmic domain and a potentially secreted isoform that is substituted within the third TNFR repeat and lacks the transmembrane and cytoplasmic regions. GITR is expressed on CD4+CD25+ regulatory T cells (Treg) as well as on subsets of thymocytes, lymph node cells, and splenocytes (4-6), and it is upregulated on antigen-activated conventional CD4+ and CD8+ T cells (3, 4, 6, 7). GITR binding by GITR Ligand/TNFSF18 costimulates the proliferation and activation of CD4+ or CD8+ conventional T cells (3, 7-9). It also induces the proliferation of Treg (8, 10) but inhibits the ability of Treg to suppress immune responses (5, 8, 11-13). This can result in the development of autoimmunity, increased tumor cell killing by effector T cells (5, 11), and increased inflammation in arthritis, allergic asthma, and inflammatory bowel disease (10, 14). GITR is also expressed on sympathetic neurons where it enhances NGF-induced neurite outgrowth and branching (15).
Source : CHO cells
Species : Human
Tag : Fc&Avi
Predicted N Terminal : Gln26 inferred from enzymatic pyroglutamate treatment revealing Arg27
Form : Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
Bio-activity : Measured by its binding ability in a functional ELISA. When Recombinant Human TNFSF18 is immobilized at 0.5 μg/mL (100 μL/well), It binds to Biotinylated Recombinant Human TNFRSF18 Fc Chimera Avi-tag with an ED50 of 0.05-0.5 μg/mL.
Molecular Mass : 54-60 kDa, under reducing conditions
Protein length : Gln26-Glu161
Endotoxin : <0.10 EU per 1 μg of the protein by the LAL method.
Purity : >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Applications : Bioactivity
Storage : Use a manual defrost freezer and avoid repeated freeze-thaw cycles.12 months from date of receipt, -20 to -70 °C as supplied.1 month, 2 to 8 °C under sterile conditions after reconstitution.3 months, -20 to -70 °C under sterile conditions after reconstitution.
Reconstitution : Reconstitute at 500 μg/mL in PBS.
Gene Name : TNFRSF18 tumor necrosis factor receptor superfamily, member 18 [ Homo sapiens ]
Official Symbol : TNFRSF18
Synonyms : TNFRSF18; tumor necrosis factor receptor superfamily, member 18; tumor necrosis factor receptor superfamily member 18; AITR; CD357; GITR; activation-inducible TNFR family receptor; glucocorticoid-induced TNFR-related protein; TNF receptor superfamily activation-inducible protein; GITR-D;
Gene ID : 8784
mRNA Refseq : NM_004195
Protein Refseq : NP_004186
MIM : 603905
UniProt ID : Q9Y5U5

Not For Human Consumption!

Inquiry

  • Reviews
  • Q&As

Customer Reviews (3)

Write a review
Reviews
12/20/2021

    This flexibility enables researchers like myself to tailor TNFRSF18 protein experiments to our unique needs, enhancing the reliability and relevance of the obtained results.

    03/05/2020

      Their commitment to delivering exceptional products and assisting with any challenges that may arise ensures a successful and rewarding experimental journey.

      10/01/2017

        The TNFRSF18 protein offered by the manufacturer is of exceptional quality, and it meets the rigorous standards necessary for my experimental needs.

        Q&As (5)

        Ask a question
        What are some current clinical trials involving TNFRSF18-targeted therapies in cancer treatment? 12/20/2022

        Clinical trials are investigating TNFRSF18 agonists, such as monoclonal antibodies, in combination with other cancer treatments in various cancer types.

        Are there any approved TNFRSF18-targeted therapies for cancer treatment? 06/29/2019

        As of my knowledge cutoff date in January 2022, there were no approved TNFRSF18-targeted therapies for cancer. However, this may have changed since then.

        Are there potential side effects associated with TNFRSF18-targeted therapies? 12/30/2018

        Side effects may include immune-related adverse events, similar to those seen with other immunotherapies, and can range from mild to severe.

        How can TNFRSF18-targeted therapies potentially improve cancer outcomes? 05/05/2018

        TNFRSF18-targeted therapies may enhance the body's immune response against cancer cells, leading to better tumor control and improved patient outcomes.

        Can TNFRSF18-targeted therapies be used in combination with other immunotherapies? 05/20/2016

        Yes, combination therapies involving TNFRSF18 agonists and other immunotherapies are under investigation to improve treatment efficacy.

        Ask a Question for All TNFRSF18 Products

        Required fields are marked with *

        My Review for All TNFRSF18 Products

        Required fields are marked with *

        0

        Inquiry Basket

        cartIcon
        logo

        FOLLOW US

        Terms and Conditions        Privacy Policy

        Copyright © 2025 Creative BioMart. All Rights Reserved.

        Contact Us

        • /
        • Service lnquiry:

        Stay Updated on the Latest Bioscience Trends